Table 2. Characteristics of HIV infected patients in Chronic HIV care who took IPT in SNNP region, Ethiopia, September 2007 to August 2010.
| Category | Sub-category | Total | Took IPT, n (%) | RR (95% CI) | P value |
| Total | 5407 | 2131 (39) | |||
| Age (years) | <15 | 475 | 125 (26) | 1.0 | |
| 15–50 | 4683 | 1898 (41) | 1.54 (1.34–1.77) | <0.001 | |
| >50 | 249 | 108 (43) | 1.65 (1.34–2.03) | <0.001 | |
| Sex | Female | 3095 | 1279 (41) | 1.0 | |
| Male | 2312 | 852 (37) | 0.89 (0.83–0.95) | <0.001 | |
| WHO Stage | Stage 1 and 2 | 3182 | 1318 (41) | 1.0 | |
| Stage 3 and 4 | 2225 | 813 (37) | 0.88 (0.82–0.94) | <0.001 | |
| CPT initiation | Yes | 3926 | 1751 (45) | 1.0 | |
| No | 1481 | 380 (26) | 0.58 (0.52–0.63) | <0.001 | |
| Baseline CD4 (count/mm3) | <100 | 1002 | 345 (34) | 1.0 | |
| 100–199 | 1545 | 635 (41) | 1.19 (1.08–1.33) | 0.001 | |
| 200–349 | 1590 | 638 (40) | 1.17 (1.05–1.29) | 0.004 | |
| ≥350 | 1270 | 513 (40) | 1.17 (1.05–1.31) | 0.004 | |
| ART initiation | Yes | 3183 | 1606 (50) | 1.0 | |
| No | 2224 | 525 (24) | 0.47 (0.43–0.51) | <0.001 |
IPT-Isoniazid Preventive Therapy; ART-antiretroviral therapy; CPT-Cotrimoxazole Preventive Therapy; WHO-World Health Organization; HIV-Human Immunodeficiency virus.